<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395263</url>
  </required_header>
  <id_info>
    <org_study_id>Yuxintine Capsule-MDD-Ⅱb</org_study_id>
    <secondary_id>2012ZX09303-003</secondary_id>
    <nct_id>NCT02395263</nct_id>
  </id_info>
  <brief_title>Comparison of Yuxintine With Placebo in Treatment of MDD</brief_title>
  <official_title>Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Innovative Research Center of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Yuxintine Capsule in different doses are
      effective in the treatment of Depression.

      And to explore the preliminary information of safety and efficacy of Yuxintine Capsule in the
      Chinese Patients with Depression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in MADRS scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical remission rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI(CGI-S,CGI-I)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreasing rate from baseline in HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical remission rate according to HAMD</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in HAMA</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese Medicine Syndrome Scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>vital sign</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood pressure, heart rate, temperature and respiratory rate</description>
  </other_outcome>
  <other_outcome>
    <measure>The Arizona Sexual Experience Scale (ASEX)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory examination</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood RT, Urinalysis,Hepatic function,Renal function,FBG,Lipid,Thyroid Function, Blood Coagulation Test and U-HCG</description>
  </other_outcome>
  <other_outcome>
    <measure>AE(adverse events)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Early Termination</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>Yuxintine 200mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yuxintine 200mg oral, once a day, 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yuxintine 300mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yuxintine 300mg oral, once a day, 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yuxintine 400mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yuxintine 400mg oral, once a day, 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral, once a day, 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yuxintine</intervention_name>
    <arm_group_label>Yuxintine 200mg per day</arm_group_label>
    <arm_group_label>Yuxintine 300mg per day</arm_group_label>
    <arm_group_label>Yuxintine 400mg per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria
             of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic
             symptoms. Coding of diagnosis included: 296.2 and 296.3.

          -  The Subject with Heart-Spleen Deficiency based on the CTM.

          -  The total score of MADRS is ≥22 in both screening visit and baseline visit.

          -  The total score of HAMD-17 is ≥18 and ≤30, AND item 1 ≥2 in both screening visit and
             baseline visit.

          -  The subject understands and consents to takes part in this clinical trials. The
             subjects should sign informed consent.

        Exclusion Criteria:

          -  The subject made a suicide attempt in recent 6 months or has a score ≥3 on item
             3(suicide assessment) of the HAMD.

          -  The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.

          -  When the MADRS score of baseline visit compares with the screening visit, the
             decreasing rate is ≥25%.

          -  Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction),
             blood(e.g. bleeding tendency),or other medical disease.

          -  Had a history of seizure disorder,except infantile febrile convulsion.

          -  The subject has accepted psychosurgery or electroconvulsive therapy within 3 months.

          -  With psychotic symptoms.

          -  The subject has a history of mania episode, including manic, mixed or rapid cycle
             attack.

          -  The subject has a current diagnosis or history of depression due to any other
             psychotic disorder or a general medical condition.

          -  The subject with refractory depressive disorder,i.e.the patients who used at least two
             different mechanisms antidepressants with adequate dosage and duration treatment still
             had no respond.

          -  Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory
             values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function index
             above toplimit, abnormal coagulation function and clinical significance of
             abnormality, i.e. Prothrombin time shorten or extend more than 3 seconds or a dynamic
             variation or APTT prolonged more than 10 seconds,AND fibrinogen L or been progressive
             decline, or &gt; 4.0 g/L).

          -  The subject has a diagnosis of alcohol or other substance abuse or dependence at least
             1 years prior to the baseline visit.

          -  Known hypersensitivity to Ginseng, or at least to two kinds of drugs, or serious
             allergic physique.

          -  Women who were pregnant, breast-feeding, or planning to become pregnant during study.
             Men who have request to fertility during study period. The subject could not take safe
             and effective birth control measures.

          -  The subject could not take medication according to the doctor's advice.

          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops
             using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more
             than 2 weeks).

          -  The subject has participated in a drug clinical trial within 3 months before
             screening.

          -  The investigator think the subject is unsuitable to enrol in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huafang LI, MD PhD</last_name>
    <phone>86-21-34773128</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yifeng SHEN, MD PhD</last_name>
    <phone>86-21-34773215</phone>
    <email>shenyifeng@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongyan ZHANG, MD</last_name>
      <phone>13601237138</phone>
      <email>sally_zhy@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaoxiao YAN, MD</last_name>
      <phone>18513880816</phone>
      <email>13811217058@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaqing MENG, MD</last_name>
      <phone>13320248988</phone>
      <email>mhq99666@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Mental Health Center</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiebang LIU, MD</last_name>
      <phone>13823501800</phone>
      <email>Liutbsz@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqing TAO, MD</last_name>
      <phone>18607713688</phone>
      <email>tjq3238@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guiyang Medical College</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiming WANG, MD</last_name>
      <phone>13511967666</phone>
      <email>754603457@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Mental Health Center</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuxin LI, MD</last_name>
      <phone>13931292966</phone>
      <email>liuyuanliyuxin@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Brain Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiansheng GUO, MD</last_name>
      <phone>13808431145</phone>
      <email>1945461929@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Anding Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300074</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi WANG, MD</last_name>
      <phone>13820826767</phone>
      <email>adyy003@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

